Related Experiment Videos
[Problems with anti-arrhythmia therapy in atrial fibrillation]
G Breithardt1, H Kottkamp, W Haverkamp
1Medizinische Klinik und Poliklinik, Westfälische Wilhelms-Universität Münster.
Zeitschrift Fur Kardiologie
|January 1, 1994
Summary
Atrial fibrillation (AF) management involves choosing antiarrhythmic drugs carefully to balance benefits and risks. Understanding AF
Area of Science:
- Cardiology
- Pharmacology
Context:
- Atrial fibrillation (AF) prevalence increases with age, affecting 2-5% of individuals over 60.
- Patients with AF can experience severe symptoms, hemodynamic compromise, or thromboembolic events.
Purpose:
- To review antiarrhythmic drug treatment strategies for atrial fibrillation.
- To discuss the mechanisms of action for antiarrhythmic drugs in managing AF.
- To highlight challenges in selecting appropriate therapies and balancing risks versus benefits.
Summary:
- Atrial fibrillation is often maintained by multiple reentrant wavelets; antiarrhythmic drugs can terminate or prevent AF by altering refractory periods and conduction velocity.
- Vaughan Williams Class Ia, Ic, and III drugs are effective for AF conversion and recurrence prevention.
- Ventricular rate control is achieved with digitalis, beta-blockers, and verapamil.
Impact:
- Informed clinical decisions regarding antiarrhythmic drug selection for atrial fibrillation.
- Improved understanding of the complex interplay between arrhythmia mechanisms and pharmacological interventions.
- Guidance on weighing the benefits of restoring sinus rhythm against treatment risks.